5-ethyl-4-iodomethyl-2-(4-isopropylphenyl)oxazole | 752212-93-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-ethyl-4-iodomethyl-2-(4-isopropylphenyl)oxazole
• 英文别名: 5-ethyl-4-(iodomethyl)-2-(4-propan-2-ylphenyl)-1,3-oxazole
• CAS: 752212-93-4
• 化学式: C₁₅H₁₈INO
• 分子量: 355.219
• InChiKey: PBFCTVPSJFFZSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-ethyl-4-iodomethyl-2-(4-isopropylphenyl)oxazole 、 tert-butyl 2-((1R,3S)-3-hydroxycyclohexylmethoxy)-2-methylpentanoate 生成 2-{(1R,3S)-3-[5-Ethyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy)cyclohexylmethoxy]-2-methylpentanoic acid
  参考文献：
  名称：

  2-{-3,'2-(PHENYL)-OXAZOL-4-YLMETHOXYL-CYCLOHEXYL METHOXY}-PROPIONIC ACID DERIVATIVES USED AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES

  摘要：

  本发明涵盖用于治疗代谢性疾病的化合物和组合物，尤其是那些与血液中胰岛素相关的代谢性疾病，如高脂血症、糖尿病、胰岛素抵抗等，包括具有环己基甲氧基取代基和其盐的乙酸衍生物。被称为过氧化物酶体增殖物激活受体（PPAR）激动剂/拮抗剂，本发明涉及式I的化合物，其中各个取代基R组在此更具体地定义。

  公开号：

  US20070197613A1
• 作为产物：
  描述：

  4-iodomethyl-5-phenyl-2-p-tolyloxazole 、 戊烷-2,3-二酮 2-肟 、 4-异丙基苯甲醛 以gave 5-ethyl-4-iodomethyl-2-(4-isopropylphenyl)oxazole的产率得到5-ethyl-4-iodomethyl-2-(4-isopropylphenyl)oxazole
  参考文献：
  名称：

  Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals

  摘要：

  本文提供了以下公式I的新化合物： 其中基团的定义如下，其生理上可接受的盐，其制备过程，以及治疗和/或预防患有脂肪酸代谢和葡萄糖利用障碍以及胰岛素抵抗相关疾病的方法。

  公开号：

  US07259177B2

文献信息

• Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040209920A1

  公开（公告）日：2004-10-21

  Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals The invention relates to arylcycloalkyl-substituted alkanoic acid derivatives and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for the treatment and/or prevention of disorders of the fatty acid metabolism and glucose utilization disorders and also disorders in which insulin resistance is involved.

  芳基环烷基取代的烷基酸衍生物，其制备方法及其作为药物的用途。该发明涉及芳基环烷基取代的烷基酸衍生物及其生理可接受的盐和生理功能衍生物。所描述的化合物为式I，其中基团如所定义，以及其生理可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢障碍、葡萄糖利用障碍以及胰岛素抵抗相关的疾病。
• Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040198786A1

  公开（公告）日：2004-10-07

  Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals The invention relates to cycloalkyl derivatives having bioisosteric carboxylic acid groups and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula 1, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistence is involved.

  环烷基衍生物具有生物等效羧酸基团，其制备方法及其作为药物的用途。本发明涉及具有生物等效羧酸基团的环烷基衍生物及其生理上可接受的盐和生理功能衍生物。所描述的化合物具有下式1,1中所定义的基团，以及它们的生理上可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用障碍以及胰岛素抵抗相关的紊乱。
• Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals
  申请人：Stapper Christian

  公开号：US20050215596A1

  公开（公告）日：2005-09-29

  Provided herein are cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals

  本文提供了环烷基取代的氨基酸衍生物，其制备过程以及作为药物的用途。
• ARYLYCLOALKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  申请人：Stapper Christian

  公开号：US20080167354A1

  公开（公告）日：2008-07-10

  The invention relates to arylcycloalkyl-substituted alkanoic acid derivatives and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for the treatment and/or prevention of disorders of the fatty acid metabolism and glucose utilization disorders and also disorders in which insulin resistance is involved.

  该发明涉及芳基环烷基取代的脂肪酸衍生物及其生理上可接受的盐和生理功能衍生物。所描述的是公式I中的化合物，其中基团如定义的那样，以及它们的生理上可接受的盐和制备它们的过程。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍以及胰岛素抵抗有关的疾病。
• CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  申请人：STAPPER Christian

  公开号：US20080015238A1

  公开（公告）日：2008-01-17

  Provided herein are methods for the treatment of metabolic diseases such as disorders of fatty acid metabolism and glucose utilization as well as disorders in which insulin resistance is involved, in a patient. comprising the administration of novel compounds of formula I below: in which the substituents are defined herein including their physiologically acceptable salts,

  本文提供了一种治疗代谢性疾病的方法，例如脂肪酸代谢和葡萄糖利用障碍，以及胰岛素抵抗参与的疾病，包括给患者注射以下公式I中的新化合物：其中置换基在此被定义，包括其生理上可接受的盐。